Impel NeuroPharma has developed the Precision Olfactory Delivery (POD® ) device to achieve consistent medicine delivery to the upper nasal cavity giving rapid uptake and higher bioavailability relative to standard nasal sprays. This study with dihydroergotamine mesylate (DHE) for migraine treatment compares safety, tolerability, bioavailability and pharmacokinetics (PK) of INP104...

IV DHE is effective for acute migraine. The approved label warns of potential cardiovascular effects although the clinical experience of DHE in 70 years of use has been good. Work has shown the high Cmax of IV DHE may account for a different safety profile through increased adrenergic receptor binding....

Impel NeuroPharma has developed the POD device to generate rapid, consistent systemic levels of drugs for neurological diseases. This work was to develop a L-dopa powder formulation delivered by the POD device that results in plasma exposure in rats and non-human primates (NHP), that when extrapolated to humans, will be...

January 2019 - INP104 met the predefined statistical criteria for comparative bioavailability with IV DHE and Migranal. The shorter time to reach Cmax and at 4 times the plasma concentration of DHE in comparison to Migranal combined with a favorable tolerability profile support further investigation of INP104 as an effective,...

August 2018 - This study, administering L-dopa to the vascular-rich upper nasal space with the novel POD device should guide further clinical development for an easy self or care-giver administered, rapidly effective treatment to abort OFF episodes in PD....